Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing vitiligo.

A pumpless microfluidic system is disclosed that can be used to mimic the interaction of organ systems with the immune system. Also disclosed is a method for mimicking an immune system, comprising culturing a plurality of organ cells and at least one population of immune cells in the disclosed pumpless microfluidic system under physiological conditions. The method can further comprise activating an immune reaction in the pumpless microfluidic system, continuing the culture for a defined period, collecting a sample of culture medium from the system, and assaying the sample for one or more indicators of an immune response.

The present invention features biomarkers for diagnosis and treatment of dermatological diseases, e.g., psoriasis and atopic dermatitis. The disclosure provides a minimally invasive method of determining levels of biomarkers (e.g., NOS2/iNOS) in surface skin samples.

This disclosure relates to the field of mass spectrometry analysis. In some embodiments, the disclosure relates to compositions and methods for detecting and quantifying proteins in the AKT-mTOR pathway by immunoprecipitation enrichment followed by mass spectrometry analysis.

A composition according to an embodiment includes a first population of transformed mammalian cells with a transforming growth factor beta (TGF-β), the first population having a TGF-β expression level of 0.65 ng/10.sup.5 cells/24 hours or more, and a second population of mammalian cells which are not transformed with the transforming growth factor beta, the second population having an expression level of a thrombospondin 1 (TSP-1) expression level of 31 ng/10.sup.5 cells/24 hours or more.

The present disclosure relates to compositions of oligonucleotide (e.g., SMAD7 antisense oligonucleotide diastereomers) and methods of manufacturing, assessing efficacy, and using the compositions.

The present invention relates to a novel antibody and antibody fragment that specifically binds to TNFR2 and to a composition comprising said antibody or antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or an antibody fragment thereof and a host cell comprising the same, and to a related use thereof. Besides, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.

The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoantibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.

The present disclosure relates to methods for generating blood protein profiles from whole blood, red blood cell enriched blood samples, or red blood cell components. The methods involve the comparison of protein levels before and after incubation with protease inhibitors, or the comparison of protein levels after incubation in the presence and absence of protease inhibitors. The protein profiles are used for monitoring and diagnosing diseases and disorders in subjects including colorectal cancer and preeclampsia.

The present invention provides methods of treating inflammation associated with infection, and methods of preventing or reducing the severity of sepsis caused by inflammation associated with infection, in an individual comprising, consisting essentially of or consisting of the steps of administering a therapeutically effective amount of idronoxil, or derivative, pharmaceutically acceptable salt, ester, amide, polymorph and/or prodrug thereof to the individual, wherein the individual is diagnosed with, or suspected of having, early stage organ damage caused by inflammation associated with infection.